Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
MorphoSys 4 ADR Representing Ord Shs
MPSYF
Primary Symbol:
MOR
Alternate Symbol(s):
MPHSF
Healthcare
Technology
Biotechnology
Scientific & Technical Instruments
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma...
(DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:MOR)
New Post
View:
Posts & Comments
Threaded Posts
(119)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jun 15, 2024 11:30pm
(MOR) Pivots Trading Plans and Risk Controls
News; $MOR (MOR) Pivots Trading Plans and Risk Controls2024-06-15 22:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to
...more
(119)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 29, 2024 9:15pm
MorphoSys AG Reports First Quarter 2024 Financial Results
Just In: $MOR MorphoSys AG Reports First Quarter 2024 Financial Results@ Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash, representing a
...more
(119)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 05, 2024 12:45pm
MorphoSys Stock Soars After Report Says Novartis To Acquire
Breaking News: $MOR MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer | BenzingaMorphoSys AG (NASDAQ:MOR) shares are trading higher Monday following a report suggesting
...more
(119)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Feb 05, 2024 11:45am
MorphoSys AG (NASDAQ: MOR) Near the Top of Equities by Perce
JUST IN: $MOR MorphoSys AG (NASDAQ: MOR) Near the Top of Equities by Percentage Gain on 2/5MorphoSys AG (NASDAQ: MOR) is one of today's top gainers. The company's shares have moved -3.78% on
...more
(119)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jan 30, 2024 3:30am
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product
Just In: $MOR MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial LiabilityPreliminary 2023 Monjuvi U.S. net
...more
(61)
•••
Nibinator
X
View Profile
View Bullboard History
Post by
Nibinator
on Oct 30, 2023 8:31am
Real stock price share value
13$
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Uranium Explorer to Commence Drill Program at Clearwater West Project in Saskatchewan